AbSci

Historical price data

Absci is on a mission to create better biologics for patients, faster, by unlocking novel biology with generative AI. Founded in 2011, the company has built a unique 'lab-in-the-loop' platform that iterates between generating massive proprietary datasets, training AI models for de novo design and optimization, and validating millions of designs weekly in its wet lab. With over 25 programs in its partnered and internal pipeline, including a lead candidate for androgenetic alopecia, Absci is positioning itself as a leader in the AI-driven biotherapeutics space.

The Integrated Drug Creation™ Platform combines proprietary high-throughput wet lab data generation (SoluPro®, ACE Assay) with generative AI models for de novo antibody design and multiparametric optimization, operating in iterative six-week cycles from design to validation.

1 drug in pipeline

Absci competes with AI-driven drug discovery firms like Recursion, Exscientia, and Generate:Biomedicines. Its key differentiation is its integrated, proprietary wet-lab data generation engine that fuels a closed-loop 'AI design → wet-lab validation' cycle, with a specific focus on de novo biologics design against difficult targets.